COVID-19 Treatment: A Review of Early and Emerging Options
Erin K McCreary, PharmD, BCPS, BCIDP, on behalf of the Society of Infectious Diseases Pharmacists, Jason M Pogue, PharmD, BCPS, BCIDP, on behalf of the Society
Erin K McCreary, PharmD, BCPS, BCIDP, on behalf of the Society of Infectious Diseases Pharmacists, Jason M Pogue, PharmD, BCPS, BCIDP, on behalf of the Society
mRNA-1273 (100 μg) administered as a 3-dose primary series and an additional dose was well-tolerated among solid organ transplant recipients. Antibody responses
An updated version of PASTEUR will help advance the bill in Congress.
“Unfortunately, it seems like we’re running out of antibiotic options to treat this infection.”
ID Week has partnered with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to create a Fellows Exchange Program. Through the program, two…
Abstract. Chimeric antigen receptor (CAR) T-cell therapy is a novel immunotherapy approved for the treatment of hematologic malignancies. This therapy lead
A study compared conventional versus short antibiotic duration in patients with moderate or severe cholangitis. Read IDSA’s Journal Club review by Aldon Li, MD, MD,…
During these virtual small group sessions, you can discuss your own specific questions, learn from others in your practice setting and better advocate for your…
A media briefing with experts from the Infectious Diseases Society of America to discuss U.S. measles outbreaks and driving factors behind them. FEATURING: Joshua Barocas,…
CLABSIs outside acute care are understudied and overlooked. This study underscores the need for CLABSI prevention initiatives targeted outside acute care.
A media briefing with experts from the Infectious Diseases Society of America to discuss U.S. measles outbreaks and driving factors behind them. FEATURING: Joshua Barocas,…